Diffusion Pharmaceuticals Gets Professional Recognition and Akers Biosciences Achieves a First

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / These two companies, one involved in cancer drug research, the other in cholesterol testing devices, both saw their stocks rise as investors heard of their noted industry achievements. The distribution channel of Akers is worth noting, and the early success of Diffusion may not be as promising as it is perceived.

RDI Initiates
Coverage:

Diffusion
Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=DFFN

Akers Biosciences
Inc. https://ub.rdinvesting.com/news/?ticker=AKER

Diffusion Pharmaceuticals advanced 81.75% to close at $4.98 on Tuesday. The stock traded between a wide range of $5.06 and a low of $2.619 on volume of 7.59 million shares traded. The company develops therapies for cancer and other hypoxia-related diseases. Stock prices yesterday leaped $2.24 a share, actually without any kind of official news release from the company. Diffusion has however said in its release on February 8th, that the company’s TSC Phase I/II Glioblastoma Multiforme clinical trial results have been published in the February 2017 Edition of The Journal of Neurosurgery.

Diffusion Pharmaceutical’s lead clinical trial drug, TSC, was tested in 59 patients. Results showed 36.3% of the patients who received a full dose of the TSC candidate were alive two years later, moderately positive compared to the historical two year survival rates that range from 27% to 30%. David Kalergis, Chairman and CEO, said,”The very encouraging data from our Phase I/II clinical trial supports our strategy to advance into Phase III clinical development.”

Access RDI’s Diffusion Pharmaceuticals Research Report
at: https://ub.rdinvesting.com/news/?ticker=DFFN

Akers Biosciences exploded 67.86% to close at $2.35 on Tuesday. The stock traded between $2.90 and $1.80 on volume of 7.34 million shares traded. The company has received its first order for its primary FDA approved product, rapid cholesterol self-test from First Check diagnostics. Akers Bio’s Tri-Cholesterol “Check” test is the only combined rapid cholesterol test that provides an accurate estimate of a person’s total cholesterol and their High Density Lipoprotein (“HDL”) cholesterol levels. The potential for the product is tremendous, as it is disposable, requires only a finger-stick blood sample (much like diabetic blood testing kits), and gives a result in 5 minutes. The significance of this first order is that First Check products are sold at a number of major retailers: CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop and Shop, Giant and ShopKo, among others.

Access RDI’s Akers Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=AKER

Our Actionable Research on Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) and Akers Biosciences Inc. (NASDAQ: AKER) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458440